ATAI Life Sciences NV (ATAI)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about ATAI Life Sciences NV (ATAI)
Company Performance

Current Price

as of Oct 16, 2024

$1.21

P/E Ratio

N/A

Market Cap

$203.04M

Description

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.

Metrics

Overview

  • HQBerlin, BE
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerATAI
  • Price$1.21+11.01%

Trading Information

  • Market Cap$203.04M
  • Float69.77%
  • Average Daily Volume (1m)577,025
  • Average Daily Volume (3m)567,305
  • EPS-$0.36

Company

  • Revenue$0.38M
  • Rev Growth (1yr)58.72%
  • Net Income-$57.31M
  • Gross Margin69.96%
  • EBITDA Margin-9,394.51%
  • EBITDA-$25.65M
  • EV$128.20M
  • EV/Revenue339.14
  • P/EN/A
  • P/S513.41
  • P/B1.21
Documents
SEC Filings
8-K (2024-10-04)
8-K (2024-08-14)
8-K (2024-08-13)
8-K (2024-06-05)
8-K (2024-05-23)
8-K (2024-05-15)
8-K (2024-03-28)
8-K (2024-02-06)
8-K (2024-01-23)
8-K (2024-01-09)
8-K (2024-01-04)
8-K (2023-11-14)
8-K (2023-10-13)
8-K (2023-09-29)
8-K (2023-08-31)
8-K (2023-08-10)
8-K (2023-05-31)
8-K (2023-05-17)
8-K (2023-05-11)
8-K (2023-03-24)
10-Q (2024-08-13)
10-Q (2024-05-15)
10-Q (2023-11-14)
10-Q (2023-08-10)
10-Q (2023-05-11)
10-K (2024-03-28)
10-K (2023-03-24)
Factset Street Account
ATAI Life Sciences reports Q3 EPS $0.25 including items vs year-ago ($0.22) ($1.15, 0.00) (2023-11-14T12:08:40Z)
ATAI Life Sciences completes phase 1 study of VLS-01 in healthy participants ($1.24, 0.00) (2023-10-02T20:15:45Z)
ATAI Life Sciences announces CFO Stephen Bardin has gone on parental leave - 8-K ($1.28, 0.00) (2023-10-13T20:18:00Z)
Earnings Calls
Earnings Report 2022Q3
Earnings Report (2022-11-11)
Factset
Factset Business Description